**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Y. Qui, et al.

Serial No.: 10/770,290

Filed: February 2, 2004

For: CONTROLLED RELEASE

FORMULATION OF DIVALPROEX SODIUM

Case No.: 6437.US.C4

Examiner: Not yet assigned

Group Art Unit: 1615

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to

----

Commissioner for Patents PO Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: June 1, 2004

6/1/04

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The cited references are listed on attached form PTO-1449.

☐ A copy of each cited reference is provided;

Copies of cited references are not provided because each has previously been made of record in the parent application, or is otherwise known to be in the Examiner's possession.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the above-identified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the

Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard to payment of a fee:

No fee is due because:

This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).

Applicants certify that each reference cited in this Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).

This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of \$180.00 is specified by 37 C.F.R. §1.17(p).

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025. A duplicate sheet of this page is enclosed.

23492

ABBOTT LABORATORIES Telephone: (847) 938-3508

Facsimile: (847) 938-2623

Respectfully submitted,

Y. Qui et al.

Paul D. Yasger

Registration No. 37,477 Attorney for Applicants JUN 0 & 2004 E

Sheet 1 of 2 FORM PTO-1449 **U.S. Department of Commerce** Atty. Docket No. Serial No. (Rev. 2032) **Patent and Trademark Office** 6437.US.C4 10/770,290 INFORMATION DISCLOSURE Applicant STATEMENT BY APPLICANT Qiu, et al. (Use several sheets if necessary) Filing Date Group February 2, 2004 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
	4,369,172	01/18/83	Schor et al.		1	
	4,699,927	10/18/87	Deboeck			
	4,913,906	04/03/90	Friedman et al			
	4,988,731	01/29/91	Meade			
	5,009,897	04/23/91	Brinker et al			
	5,017,613	05/21/91	Aubert, et al.			
	5,019,398	05/28/91	Daste			
****	5,055,306	10/08/91	Barry et al			
	5,169,642	12/08/92	Brinker et al			
	5,185,159	02/09/93	Aubert et al			
	5,212,326	05/18/93	Meade			
	5,589,191	12/31/96	Ukigaya et al			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Name	Class	Subclass	Translation (Yes No)
 94/27587	08.12.94	wo			
00/37055	29.06.00	WO			
00/45793 A1	08/10/00	WO			
98/47491	29.10.98	WO			
0 430 287 B2	06/05/91	EP		-	
0 141 267 B1	08/05/87	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CTILLING.	DOCOMENTS (including Author, Title, Date, Pertinent Pages, Etc.)				
	Bialer et al., Int. J. Pharmaceutics, 20: 53-63 (1984)				
	Bialer et al., Biopharmaceutics and Drug Disposition, 6: 401-411 (1985)				
	Bialer et al., Israel J. Med. Sci., 20: 46-49 (1984)				
	Collins et al., Extended Release Formulations of Anticonvulsant Medications Clinical Pharmacokinetics and Therapeutic Advantages, CNS Drugs 2000 Sept 14 (3): 203-212				
	Freitag, et al., "Depakote ER in Migraine Prophylaxis", Abstract No. S07.003, Nuerology 54 April 2000 (Suppl 3), page A14.				
	Physicians' Desk Reference, (Web Version), 2001, Depakote ER, published by The Medical Economics Company				
	"Metabolism of Antiepiliptic Drugs", 143-151, R.H. Levy, Ed. Raven Press, New York (1984)  **Physicians' Desk Reference. 54th Edition, 2000, Depakene Capsules, pp. 426-427, published by Medical Economic Company, Inc.				
	Physicians' Desk Reference. 54 <sup>th</sup> Edition, 2000, Depakote Tablets, pp. 431-437, published by Medical Economic Company, Inc.				
	Package insert for Depakote® ER dated August 2000				
EXAMINER	DATE CONSIDERED				

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Rev. 2032)	RM PTO-1449 U.S. Department of Commerce ev. 2032) Patent and Trademark Office					Atty. Docket No. 6437.US.C4		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Applicant Qiu, et al. Filing Date		10/770,290 Group 1615	
								U.
Examiner Initial	Document Number	Date	Name	Class	Subclass	Subclass Filing Date (if appro		
	5,593,690	01/18/83	Schor et al.	l	1			
	5,593,694	01/14/97	Akiyama et al.	]				
	5,980,913	11/09/99	Ayer et al.					
	6,077,542	06/20/00	Sherman	İ		1		
	6,150,410	11/21/00	Engh, et al.					
FC	OREIGN PATENT DOCUI	MENTS		<u> </u>	1			
	Document Number	Date	Name	Class	Subclass	Translat	tion (Yes No)	
	<del></del>	-		<del></del>				
0	THER DOCUMENTS (Inc	luding Author,	Title, Date, Pertine	nt Pages.	Etc.)			
	Pharmacokinet Abstract of Bia	Abstract of Collins, et al., "Extended Release Formulations of Anticonvulsant Medications Clinica Pharmacokinetics and Therapeutic Advantages", CNS Drugs, New Zealand, 2000, 14/3 (203-212) Abstract of Bialer, et al., "Criteria to Assess in Vivo Performance and Bioequivalence of Generic Controlled-Release Formulations of Carbamazepine", Epilepsia, United States, 1998, 39/5 (513-						
		Abstract of Chun, et al., "Multiple-dose Evaluation of the Absorption Characteristics of Divalproes Sodium Tablets, a Delayed-Release Preparation of Valproate, in Healthy Volunteers", Clinical Dru Investigation, New Zealand, 1995, 10/1 (40-47)						
	Sodium Tablets Investigation, N	, a Delayed-Rele lew Zealand, 19	ease Preparation of ' 95, 10/1 (40-47)	Valproate,	in Healthy Vo	lunteers"	of Divalproe , Clinical Dru	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14	s, a Delayed-Rellew Zealand, 19 ssolle, et al., "A elease Oral Sodi (61-1464)	ease Preparation of 95, 10/1 (40-47) Double Weibull Inpum Valproate", Jour	Valproate, out Functional of Phar	n Describes the	olunteers" ne Comple ciences, U	of Divalproe C, Clinical Dru ex Absorption Inited States,	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology,	s, a Delayed-Rel- lew Zealand, 19 ssolle, et al., "A elease Oral Sodi (61-1464) sein, et al., "Phausion Administr United States, 1	ease Preparation of '95, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Validon: Gastrointestin 994, 34/7 (754-759)	Valproate, out Function nal of Phar alproate aft al-related I	in Healthy Von Describes the maceutical Source Multiple-do Diurnal Varia	olunteers"  ne Compleciences, U  ose Oral attion", Jou	of Divalproe C, Clinical Dru ex Absorption United States, and rmal of Clinic	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology, Abstract of Wil States, 1983, 33	s, a Delayed-Rel- lew Zealand, 19 ssolle, et al., "A elease Oral Sodi (61-1464) sein, et al., "Phausion Administr United States, 1 der, et al., "Gast (6/6/808-811)	ease Preparation of 95, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Valtion: Gastrointestin 994, 34/7 (754-759) rointestinal Tolerand	valproate, but Functional of Phar alproate aft al-related I	in Healthy Von Describes the maceutical Soler Multiple-dolurnal Variation proex Sodium	ne Compleciences, Uose Oral attion", Jou	of Divalproe C, Clinical Dru ex Absorption United States, and rmal of Clinical	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology, Abstract of Wil States, 1983, 33 Abstract of Wil Pharmacology	s, a Delayed-Reliew Zealand, 19 ssolle, et al., "A selease Oral Sodi 61-1464) sein, et al., "Pha usion Administr United States, 1 der, et al., "Gast 66 (808-811) der, et al., "Twic and Therapeutics	ease Preparation of '95, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Valtion: Gastrointestin 994, 34/7 (754-759) rointestinal Tolerande-de-daily Dosing of Valuations, United States, 198	valproate, but Functional of Phar alproate after al-related I ce of Dival alproate w 3, 34/4 (50	in Healthy Von Describes the maceutical Soler Multiple-dolurnal Variation proex Sodium ith Divalproes 1-504)	ne Compleciences, Uose Oral attion", Jou	of Divalproe C, Clinical Dru ex Absorption United States, and rmal of Clinical logy, United	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology, Abstract of Wils States, 1983, 33 Abstract of Wils Pharmacology a Colins, et al., "I Formulation for	s, a Delayed-Reliew Zealand, 19 ssolle, et al., "A selease Oral Sodi 61-1464) sein, et al., "Pha usion Administr United States, 1 der, et al., "Gast 66 (808-811) der, et al., "Twic and Therapeutics Depakote CR: B Once Daily Do	ease Preparation of 95, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Valtion: Gastrointestin 994, 34/7 (754-759) rointestinal Tolerance-daily Dosing of Valuited States, 198 iopharmaceutical anising", Neurology, V	valproate, but Functional of Phar alproate aft al-related I ce of Dival (alproate w 3, 34/4 (50 d Pharmace ol. 50(4), S	in Healthy Von Describes the maceutical Soler Multiple-dolumnal Variation Process Sodium (1-504)  Divinetic Studiosupplement 4,	ne Compleciences, Uose Oral attion", Journ', Neurolex", Clinic ies of a New April 196	of Divalproe C, Clinical Dru ex Absorption United States, and rmal of Clinical logy, United al ew 98, p. A426	
	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology, Abstract of Wil States, 1983, 33 Abstract of Wil Pharmacology a Colins, et al., "I Formulation for Samara, et al., " Epilepsia, Vol.	s, a Delayed-Reliew Zealand, 19 ssolle, et al., "A selease Oral Sodi 61-1464) sein, et al., "Pha usion Administr United States, 1 der, et al., "Gast 66 (808-811) der, et al., "Twic and Therapeutics Depakote CR: B Once Daily Do Bioavailability o 38, Suppl. 8, 19	ease Preparation of 195, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Valtion: Gastrointestin 1994, 34/7 (754-759) rointestinal Tolerand 1994, 34/7 (754-759) re-daily Dosing of Value States, 198 iopharmaceutical and 1997 of a Controlled-Relevant	valproate, but Functional of Phar alproate aft al-related I ce of Dival alproate w 3, 34/4 (50 d Pharmace ol. 50(4), S ase Formul	in Healthy Von Describes the maceutical Soler Multiple-dolumnal Varian proex Sodium ith Divalproex 1-504) okinetic Studioupplement 4, ation of Department 4	ne Compleciences, Uose Oral attion", Journ', Neurolex", Clinic es of a New April 190	of Divalproe c, Clinical Druex Absorption United States, and rmal of Clinical logy, United al ew 98, p. A426 p. 3.053,	
XAMINER	Sodium Tablets Investigation, N Abstract of Bre of Sustained-Re 1994, 83/10 (14 Abstract of Hus Intravenous Inf Pharmacology, Abstract of Wils States, 1983, 33 Abstract of Wils Pharmacology a Colins, et al., "I Formulation for Samara, et al., " Epilepsia, Vol. Cavanaugh, et a Depakote Unde	s, a Delayed-Reliew Zealand, 19 ssolle, et al., "A selease Oral Sodi 161-1464) sein, et al., "Pha usion Administr United States, 1 der, et al., "Gast 1/6 (808-811) der, et al., "Twic and Therapeutics Depakote CR: B Once Daily Do Bioavailability (38, Suppl. 8, 19 1., "Effect of Fo	ease Preparation of 95, 10/1 (40-47) Double Weibull Inpum Valproate", Journacokinetics of Valtion: Gastrointestin 994, 34/7 (754-759) rointestinal Tolerande-daily Dosing of Valunted States, 198 (apharmaceutical and sing", Neurology, Vof a Controlled-Rele	Valproate, but Functional of Phar alproate aft al-related I ce of Dival Valproate w 3, 34/4 (50 d Pharmace ol. 50(4), S ase Formul	in Healthy Von Describes the maceutical Soler Multiple-dolumnal Varian proex Sodium ith Divalproe: 1-504) okinetic Studiouplement 4, ation of Deparation of Deparation of Deparation Described Properties 1 (2) on trolled-Rein (2	ne Compleciences, Uose Oral attion", Journ', Neurolex", Clinic ies of a New April 190 akote", Neurolesse Forresse Forres	of Divalproe. C, Clinical Druex Absorption United States, and rmal of Clinical logy, United al ew 98, p. A426 b. 3.053, mulation of	

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.